Get the latest news, insights, and market updates on SNGX (Soligenix, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet’s Disease
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Dusquetide (SGX945) Granted Orphan Drug Designation for the Treatment of Behcet’s Disease On August 18, 2025, Soligenix, Inc., (NASDAQ:SNGX) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to dusquetide, the active ingredient in SGX945, for “treatment of Behcet’s Aug 20, 2025 - $SNGX
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for "treatment of Behçet's Disease" following review of recent Phase 2a clinical Aug 18, 2025 - $SNGX
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2025. Aug 14, 2025 - $SNGX
NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer
AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,” featuring Soligenix Inc. (NASDAQ: SNGX). To hear the NetworkNewsAudio version, visit https://nnw.fm/Tflrp To read the original editorial, visit https://nnw.fm/JoDGY Soligenix Inc. is advancing HyBryte, its late-stage therapy for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer t Aug 8, 2025 - $SNGX
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Clinical Progress in Rare Disease Signals Long-Term Re Aug 7, 2025 - $SNGX
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Late-Stage Pipeline Wins Boost Investor Confidence in Aug 5, 2025 - $SNGX
SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease…
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Encouraging Results from Phase2a Trial of SGX945 in Behcet’s Disease On July 31, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced encouraging results from a Phase 2a clinical trial of SGX945 in Behcet’s disease (BD) in which the compound exhibited biological efficacy. These results are supportive of advancing the Jul 31, 2025 - $SNGX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple